Third article in Paolo's Biotech Notes series. PDF attached and uploaded. Additionally, Paolo has provided a relevant timely article. ContraFect Corp (CFRX) has a promising pipeline with a potential ...
The third quarter was a pivotal period for both the biotech and pharmaceutical sectors, with regulatory developments and an increase in business deals shaping the landscape for the industries. Public ...
Bank of America Securities writes that SMid-cap biotech, companies with small to mid-sized market capitalizations, had a rocky start to the year. Many companies in the coverage are down 20-40% year-to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results